In 2017, Enzymatica published the results of a number of studies, including clinical studies, market research and an in-vitro study on the use of ColdZyme® Mouth Spray. The results are clear and show the positive properties of the product to prevent and treat colds

Full Article: COLDPREV – A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold. Oct 2017
 
Article: A medical device forming a protective barrier that deactivates four major common cold viruses (Rhinovirus type 1A and type 42, Seasonal Flu virus (H3N2), Respiratory Syncytial Virus, Adenovirus type 2). Nov 2017
 
Article: Evaluation of ColdZyme Mouth Spray against common cold in preschool staff. Oct 2017
 
Abstract: Prevention of upper respiratory tract infection among elderly care personnel and residents at a nursing home. Dec 2016
 
Patient-case report: Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infection(s) in a CVID-patient: a case report.Nov 2016

Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infections in a boy with primary immunodeficiency: a case report

Review article: Cold-Adapted Proteases as an Emerging Class of Therapeutics, Jun 2013

Cold-Adapted Proteases as an Emerging Class of Therapeutics

Review article: Potential Use of Atlantic Cod Trypsin in Biomedicine, Jan 2013

Potential Use of Atlantic Cod Trypsin in Biomedicine

 

 

This content needs to be approved before viewing.
Yes, I accept
No, I decline